Exclusive: Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Institutional Investors Sentiment Unchanged in Q2 2016

November 28, 2016 - By Marie Mckinney   ·   0 Comments

Exclusive: Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Institutional Investors Sentiment Unchanged in  Q2 2016

Sentiment for Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) institutional sentiment decreased to 1.1 in Q2 2016. Its down -0.04, from 1.14 in 2016Q1. The ratio turned negative, as 219 hedge funds opened new or increased positions, while 192 decreased and sold their equity positions in Vertex Pharmaceuticals Inc. The hedge funds in our partner’s database now have: 236.53 million shares, down from 238.13 million shares in 2016Q1. Also, the number of hedge funds holding Vertex Pharmaceuticals Inc in their top 10 positions increased from 4 to 5 for an increase of 1. Sold All: 53 Reduced: 139 Increased: 176 New Position: 43.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has a market cap of $21.62 billion. The Firm operates in pharmaceuticals segment. It currently has negative earnings. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications.

About 143,751 shares traded hands. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 2.46% since April 25, 2016 and is uptrending. It has underperformed by 3.55% the S&P500.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on January, 25. They expect $0.01 EPS, up 150.00% or $0.03 from last year’s $-0.02 per share. VRTX’s profit will be $2.49M for 2167.25 P/E if the $0.01 EPS becomes a reality. After $-0.09 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -111.11% EPS growth.

According to Zacks Investment Research, “Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)”

Blue Jay Capital Management Llc holds 7.09% of its portfolio in Vertex Pharmaceuticals Incorporated for 125,450 shares. Bb Biotech Ag owns 1.42 million shares or 4.81% of their US portfolio. Moreover, Tekla Capital Management Llc has 3.63% invested in the company for 1.03 million shares. The Minnesota-based Cornerstone Capital Management Llc has invested 3.09% in the stock. Sivik Global Healthcare Llc, a Connecticut-based fund reported 65,000 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 29 insider sales for $17.66 million net activity.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Ratings analysis reveals 56% of Vertex Pharmaceuticals’s analysts are positive. Out of 16 Wall Street analysts rating Vertex Pharmaceuticals, 9 give it “Buy”, 0 “Sell” rating, while 7 recommend “Hold”. The lowest target is $85 while the high is $160. The stock’s average target of $125.55 is 44.78% above today’s ($86.72) share price. VRTX was included in 30 notes of analysts from July 31, 2015. The firm earned “Hold” rating on Wednesday, September 9 by Jefferies. The stock has “Market Perform” rating given by BMO Capital Markets on Thursday, April 7. The rating was upgraded by Vetr to “Hold” on Monday, August 17. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Outperform” rating given on Tuesday, March 8 by Leerink Swann. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Argus Research on Monday, September 28. The stock has “Neutral” rating given by Goldman Sachs on Thursday, April 28. The company was initiated on Tuesday, December 1 by Stifel Nicolaus. H.C. Wainwright upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, October 30 to “Buy” rating. The stock has “Buy” rating given by Vetr on Tuesday, September 1. Argus Research maintained the shares of VRTX in a report on Thursday, February 4 with “Buy” rating.

VRTX Company Profile

Vertex Pharmaceuticals Incorporated (Vertex), incorporated on January 4, 1989, is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Firm operates in pharmaceuticals segment. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Vertex’s two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. The Company’s VX-661 is a corrector compound that the Company is evaluating a Phase III development program in combination with ivacaftor in multiple CF patient populations having approximately one copy of the F508del mutation in their CFTR gene. The Company’s VX-371 is an investigational epithelial sodium channel (ENaC) inhibitor that is being evaluated in a Phase II development program. The Company’s VX-152 and VX-440 are two next-generation CFTR corrector compounds that entered Phase I clinical trials.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Fool.com which released: “Vertex Pharmaceuticals Incorporated Pushes Forward With Drug Combinations (and …” on October 27, 2016, also Fool.com with their article: “Can Vertex Pharmaceuticals Incorporated Bounce Back From Its 28.9% Drop?” published on July 06, 2016, Fool.com published: “Why Vertex Pharmaceuticals Incorporated Stock Dipped 11% in March” on April 11, 2016. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Fool.com and their article: “These 2 Catalysts Lifted Vertex Pharmaceuticals Incorporated 13% in July” published on August 10, 2016 as well as Fool.com‘s news article titled: “Vertex Pharmaceuticals Incorporated Prepares for (More) Growth” with publication date: August 02, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>